55 patents currently held

Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.

12 more records may belong here and await a decision; they are not counted.

The next term ends in Apr 2027. from the record

Free plan: 3 watched companies. Pro: unlimited.

Alerts on its grants, lapses and transfers.

Ending by 2030

Apr 2027

Next term end

Patent families

When these terms end

5 yrs10 yrs20 yrs

Held patents by the year their term ends

20262027 2028 2029 2030 2031 203220332034 2035 2036 2037 2038 2039 2040 2041 2042 204320442045

notable patents fee due within 90 days all others Updated Nov 14, 2026 · includes USPTO assignment & status data published Nov 14, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know

Notable: the highest-ranked patents in this portfolio by citations and family size. Fee due within 90 days: a maintenance fee is due within 90 days of when this page was computed and not yet paid.

Notable patents

Ranked by citations and family size, against patents of the same kind granted the same year. How we rank

Notable

Compounds, Compositions, and Methods for Preventing Metastasis of Cancer Cells US 8,569,348

The most cited patent in this portfolio, cited by 118 later US patents, top 5% of utility patents granted in 2013 in our data. Protection runs to 2030.

Ends Jan 2030 · High confidence Also notable

Injectable sustained release delivery devices US 8,871,241

Cited by 85 later US patents, top 10% of utility patents granted in 2014 in our data, and renewed at 3 of 3 maintenance windows. Protection runs to 2027.

Ends Aug 2027 · High confidence Also notable

ANTIBODIES THAT BIND HUMAN PROTEIN TYROSINE PHOSPHATASE beta (HPTPbeta) AND USES THEREOF US 9,926,367

Cited by 35 later US patents, top 10% of utility patents granted in 2018 in our data, and renewed at every maintenance window due so far. Protection runs to 2027. A terminal disclaimer caps this term to an earlier patent's.

Ends Apr 2027 · High confidence

Fee deadlines

Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.

2 fees due Dec 6 to 25, 2026 · next Dec 6
1 fee due May 3, 2027
The maintenance fee for Compounds, Compositions, and Methods for Preventing Metastasis of Cancer Cells (US 9,174,950) comes due May 3, 2027. Unpaid by Nov 3, 2027, it lapses early.
1 fee due Jul 16, 2027
The maintenance fee for Method of Treating Ocular Conditions by Administering an Antibody That Activates TIE2 and Binds VEGF (US 11,873,334) comes due Jul 16, 2027. Unpaid by Jan 18, 2028, it lapses early.
2 fees due Sep 24 to 30, 2027 · next Sep 24
1 fee due Nov 10, 2027
The maintenance fee for Bioerodible Silicon-Based Devices for Delivery of Therapeutic Agents (US 9,333,173) comes due Nov 10, 2027. Unpaid by May 10, 2028, it lapses early.

Which patents, and when each one lapses · Pro

Recent changes

Sep 29Assignment recorded on 3 records: Eyepoint Pharmaceuticals, Inc. to Eyepoint, Inc. Recorded Sep 29, 2026, executed Dec 8, 2025. Conveyance as recorded: Change of Name. A recorded assignment is a filed document, not a statement of current ownership. Reel 76606, frame 675.
1 term has ended since Aug 16, 2026

What they patent

The 5 largest of its 26 families, grouped by real patent family and labeled by the earliest filing in each. No technology classification is inferred from titles.

Antibodies That Target Human Protein Tyrosine Phosphatase-Beta (HPTP-BETA) and Methods of Use Thereof to Treat Ocular Conditions	6 in force	to Jul 2037
Compounds, Compositions, and Methods for Preventing Metastasis of Cancer Cells	4 in force	to Jan 2030
Antibodies That Bind Human Protein Tyrosine Phosphatase Beta (HPTPBETA)	4 in force	to Jun 2029
Multispecific Antibodies That Target Hptp-B (VE-PTP) and VEGF	3 in force	to Sep 2039
Methods of Treating Intraocular Pressure with Activators of TIE-2	3 in force	to Sep 2036

Patents held now

Soonest term end first.

Patent	Title	Status	Expires	Confidence
US 9,926,367	ANTIBODIES THAT BIND HUMAN PROTEIN TYROSINE PHOSPHATASE beta (HPTPbeta) AND USES THEREOF In force Term ends Apr 5, 2027 · High confidence	In force	Term ends Apr 5, 2027	High confidence
US 11,814,425	ANTIBODIES THAT BIND HUMAN PROTEIN TYROSINE PHOSPHATASE beta (HPTPbeta) AND USES THEREOF In force Term ends Apr 5, 2027 · Medium confidence	In force	Term ends Apr 5, 2027	Medium confidence
US 8,524,235	Method for Treating Coronary Artery Disease Using Antibody Binding Human Protein Tyrosine Phosphatase Beta(HPTPbeta) In force Term ends May 3, 2027 · High confidence	In force	Term ends May 3, 2027	High confidence
US 7,589,212	Human Protein Tyrosine Phosphatase Inhibitors and Methods of Use held by Eyepoint Pharmaceuticals, Inc. In force Ends no later than Jun 26, 2027 · Medium confidence	In force	Ends no later than Jun 26, 2027	Medium confidence
US 7,622,593	Human Protein Tyrosine Phosphatase Inhibitors an Methods of Use held by Eyepoint Pharmaceuticals, Inc. In force Ends no later than Jun 26, 2027 · Medium confidence	In force	Ends no later than Jun 26, 2027	Medium confidence
US RE46,592	Human Protein Tyrosine Phosphatase Inhibitors and Methods of Use held by Eyepoint Pharmaceuticals, Inc. In force Term ends Jun 26, 2027 · Low confidence	In force	Term ends Jun 26, 2027	Low confidence
US 8,871,241	Injectable sustained release delivery devices In force Term ends Aug 12, 2027 · High confidence	In force	Term ends Aug 12, 2027	High confidence
US 7,998,108	Injector Apparatus and Method of Use In force Term ends Jan 12, 2028 · High confidence	In force	Term ends Jan 12, 2028	High confidence
US 8,815,284	Bioerodible Sustained Release Drug Delivery Systems In force Term ends Oct 12, 2028 · High confidence	In force	Term ends Oct 12, 2028	High confidence
US 7,795,444	Human Protein Tyrosine Phosphatase Inhibitors and Methods of Use held by Eyepoint Pharmaceuticals, Inc. In force Ends no later than Mar 28, 2029 · Medium confidence	In force	Ends no later than Mar 28, 2029	Medium confidence

10 of 55 patents shown.

Pro members see all 55.

Pro members: see all 55 patents

Also on record, not counted in the 55: 14 patents ended · 8 applications pending · 7 applications abandoned. List them

Sources and methods

Compiled from USPTO application file histories, grants and recorded assignments, with the company's own names reviewed by hand. How this record was built

Portfolio grouped automatically from ownership conveyances to the names matched to this company, usually every name that begins with its own, so it counts patents an affiliate holds; each list row names the holder of record. Security interests are excluded and ambiguous records are not reviewed by hand.

Fee due within 90 days marks a patent with a maintenance fee due within 90 days of the date this page was computed and not yet recorded paid, so it can end earlier than the bar shows. A fee left unpaid ends the patent at the close of the six month grace period that follows its due date, not on the due date itself. It is not a prediction that the fee will be missed.

Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.

Export every term end as CSV · Pro

Eyepoint, Inc.